Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 387.38A |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
19 |
| Average PDX Generation Time (days +/- SEM) | 57 ± 3 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 387.38A |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | Y |
| ERG | Y |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 387.38A | TP53 | -1.365 | 0.777 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | CDKN1B | -0.797 | 1.151 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | FANCA | -0.760 | 1.181 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | AKT1 | 0.497 | 2.822 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | MRE11A | 0.612 | 3.056 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | MLH1 | 0.637 | 3.109 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | CTNNB1 | 0.637 | 3.109 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | U2AF1 | 0.676 | 3.196 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | ARID2 | 0.717 | 3.288 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | GNAS | 0.825 | 3.542 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | MYC | 1.171 | 4.504 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | KDM6A | 1.218 | 2.326 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | KDM6A | 1.589 | 3.007 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 387.38A | AR | 4.080 | 16.907 | Gain-High | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
Clinical Information
| Sample Number | 387.38A |
|---|---|
| Sample Site | Para-tracheal lymph node |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, enzalutamide, lutetium PSMA, pembrolizumab |
Patient Information
| Patient Number | 387 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 387.38A |
| Patient Age (binned in 5 year age groups) | 60-64 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 387.38A | TP53 | 491 | 0.97 | Missense variant | '6/11 | . | 24.8 | Conflicting interpretations of pathogenicity | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 387.38A | KMT2C | 511 | 0.78 | Missense variant | '43/59 | 4.48E-05 | 23.2 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 387.38A | CRLF2 | 820 | 0.76 | Missense variant | '6/6 | . | 9.837 | Not provided | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 387.38A | NOTCH3 | 114 | 0.47 | Missense variant | '25/33 | 2.22E-05 | 16.93 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 387.38A | DPCR1 | 628 | 0.34 | Stop gained | '2/3 | . | 24.6 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 387.38A | DPCR1 | 628 | 0.34 | Stop gained | '2/3 | . | 24.6 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
No information in Drug dosing Table